Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
NOTE: If you attended the live CE activity titled "Subcutaneous Insulin Use in Adults: Addressing Risks and Optimizing Safety" that was held on December 6, 2017 during the 52nd ASHP Midyear Clinical Meeting & Exhibition in Orlando, Florida AND received CE credit (i.e. a pharmacist or pharmacy technician CE statement with ACPE Universal Activity Number 0221-9999-17-413-L05-P/T), you are ineligible to also receive CE credit for this home-study activity.
Insulin therapy, while essential to the health of millions of patients, continues to be a leading cause of serious patient harm when used in error. This activity will provide up-to-date information on the top insulin safety issues facing practitioners and an overview of ISMP’s newly-released national guidelines for safe subcutaneous insulin use. Expert speakers will discuss some of the unique challenges involved in managing complex insulin therapy across the continuum of care, including the use of concentrated insulins, insulin vials, and pens.
The target audience for this activity includes pharmacists and pharmacy technicians. Upon completion of this activity, participants will be able to:
Introduction and Overview
Michael R. Cohen, RPh, MS, ScD (hon), DPS (hon), FASHP
Complicated and Complex: Will Subcutaneous Insulin Use Ever Be Safe?
Matthew Grissinger, RPh, FISMP, FASCP
Director of Error Reporting Programs, ISMP
Recommended Subcutaneous Insulin Safe Practice Guidelines from the ISMP National Summit
Susan Paparella, MSN, RN
Vice President, ISMP
Insulin Safety: It Takes a Village
Jane Jeffrie Seley, DNP, MSN, MPH, GNP, BC-ADM, CDE, CDTC, FAADE, FAAN
Nurse Practitioner & Program Manager, Inpatient Glycemic Control Program,
Weill Cornell Division of Endocrinology, Diabetes & Metabolism, New York-Presbyterian Hospital, New York, NY
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Michael R. Cohen and Susan Paparella have no relevant commercial or financial relationships to disclose. Matthew Grissinger disclosed the following financial relationship: Spouse is employed by/receives a salary from Johnson & Johnson. Jane Jeffrie Seley disclosed the following financial relationships: Honoraria from Abbott Nutrition, Astra Zeneca and Boehringer Ingelheim/Lilly Alliance for attending advisory boards; Honorarium from Johnson & Johnson Diabetes Institute for development of professional education programs/webinars. Conflicts identified were resolved with a peer review process.
Please note: The opinions expressed in this activity should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include unlabeled indications. Use of drugs and devices outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.
Release Date: 02-15-2018
Expiration Date: 02-15-2020
This CE activity is jointly provided by ProCE, Inc. and the Institute for Safe Medication Practices (ISMP). ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-18-078-H05-P/T has been assigned to this knowledge-based home-study CE activity (initial release date 2-15-18). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. This CE activity is provided at no cost to participants. Statements of completion will be issued online at www.ProCE.com upon completion of the evaluation and post-test with a score of 70% or higher. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
This CE activity is jointly provided by ProCE, Inc. and Wild Iris Medical Education,
Inc. This activity provides 1.5 contact hours of nurse CE credit.
Wild Iris Medical Education, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This CE activity is supported by an educational grant from Lilly and Novo Nordisk.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.